Celyad Oncology SA
EBR:CYAD.BR
0.25 (EUR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.102 | 0 | 0 | 0.005 | 0.006 | 3.115 | 3.54 | 8.523 | 0.003 | 0.146 | 0 | 0.054 | 0.027 |
| Cost of Revenue
| -0.787 | 1.44 | 1.52 | 0 | 0 | 0 | 0.515 | 0.053 | 6.382 | 0.115 | 2.415 | 6.683 | 5.798 |
| Gross Profit
| 0.889 | -1.44 | -1.52 | 0.005 | 0.006 | 3.115 | 3.025 | 8.47 | -6.379 | 0.031 | -2.415 | -6.629 | -5.771 |
| Gross Profit Ratio
| 8.716 | 0 | 0 | 1 | 1 | 1 | 0.855 | 0.994 | -2,126.333 | 0.212 | 0 | -122.765 | -214.277 |
| Reseach & Development Expenses
| 3.881 | 18.928 | 20.773 | 21.591 | 25.232 | 23.577 | 22.908 | 27.675 | 5.899 | 15.865 | 2.158 | 0 | 0 |
| General & Administrative Expenses
| 5.707 | 10.337 | 9.665 | 8.995 | 8.725 | 10.387 | 9.31 | 9.744 | 7.23 | 5.016 | 2.988 | 3.713 | 2.839 |
| Selling & Marketing Expenses
| 0.215 | 0.239 | 0.434 | 0.454 | 0.607 | 0.676 | 0.761 | 0.728 | 0.891 | 0.394 | 0.206 | 0 | 0 |
| SG&A
| 7.605 | 10.337 | 9.665 | 8.995 | 8.725 | 10.387 | 9.31 | 9.744 | 7.23 | 5.016 | 2.988 | 3.713 | 2.839 |
| Other Expenses
| 0 | -9.002 | -3.529 | -4.342 | -4.578 | 7.321 | -23.792 | -2.523 | -0.222 | -0.963 | -1.02 | -0.003 | -0 |
| Operating Expenses
| 11.486 | 20.263 | 26.909 | 26.244 | 29.379 | 41.285 | 29.628 | 34.079 | 29.675 | 19.918 | 11.079 | -5.188 | 3.312 |
| Operating Income
| -10.597 | -40.857 | -26.391 | -26.239 | -29.373 | -38.17 | -52.876 | -25.609 | -29.672 | -16.437 | -11.969 | -1.441 | -9.083 |
| Operating Income Ratio
| -103.892 | 0 | 0 | -5,247.8 | -4,895.5 | -12.254 | -14.937 | -3.005 | -9,890.667 | -112.582 | 0 | -26.684 | -337.241 |
| Total Other Income Expenses Net
| 1.958 | -0.013 | -0.111 | 9.035 | 0.733 | 0.743 | -26.273 | 1.337 | 0.252 | 3.179 | -0.89 | -0.003 | -0 |
| Income Before Tax
| -8.639 | -40.87 | -26.502 | -17.204 | -28.64 | -37.427 | -56.396 | -23.612 | -29.114 | -16.453 | -12.346 | -2.153 | -9.134 |
| Income Before Tax Ratio
| -84.696 | 0 | 0 | -3,440.8 | -4,773.333 | -12.015 | -15.931 | -2.77 | -9,704.667 | -112.692 | 0 | -39.862 | -339.165 |
| Income Tax Expense
| -0.191 | 0.065 | 0.01 | 0.297 | -0.008 | -1.114 | -0.001 | -0.006 | -0.055 | -2.483 | -0 | 1.699 | 0.052 |
| Net Income
| -8.448 | -40.935 | -26.512 | -17.501 | -28.632 | -36.313 | -56.395 | -23.606 | -29.114 | -16.453 | -12.346 | -2.153 | -9.134 |
| Net Income Ratio
| -82.824 | 0 | 0 | -3,500.2 | -4,772 | -11.657 | -15.931 | -2.77 | -9,704.667 | -112.692 | 0 | -39.862 | -339.165 |
| EPS
| -0.33 | -1.81 | -1.7 | -1.26 | -2.29 | -3.26 | -5.86 | -2.53 | -3.43 | -2.44 | -3.01 | -0.34 | -1.44 |
| EPS Diluted
| -0.33 | -1.81 | -1.7 | -1.26 | -2.29 | -3.26 | -5.86 | -2.53 | -3.43 | -2.44 | -3.01 | -0.34 | -1.44 |
| EBITDA
| -9.803 | -18.811 | -25.578 | -24.192 | -27.45 | -37.365 | -16.665 | -21.889 | -27.845 | -18.044 | -11.035 | 0.44 | -6.362 |
| EBITDA Ratio
| -96.108 | 0 | 0 | -4,838.4 | -4,575 | -11.995 | -4.708 | -2.568 | -9,281.667 | -123.589 | 0 | 8.15 | -236.217 |